Close Menu

NEW YORK – Roughly three years after its launch, the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) Network has moved beyond its initial focus on lung cancer to add analyses of multiple cancer types including a prospective, multisite study.

The network is also working to incorporate additional proteomic technologies including data-independent acquisition (DIA) mass spectrometry and imaging and top-down mass spec, said Thomas Conrads, director of women's health research at Inova Fairfax Hospital and a researcher on the APOLLO initiative.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.